Skip to main content
Erschienen in: Annals of Hematology 10/2009

01.10.2009 | Original Article

Correlation between leukocytosis and thrombosis in Philadelphia-negative chronic myeloproliferative neoplasms

verfasst von: Domenica Caramazza, Clementina Caracciolo, Rita Barone, Alessandra Malato, Giorgia Saccullo, Valeria Cigna, Salvatore Berretta, Luciana Schinocca, Gerlando Quintini, Vincenzo Abbadessa, Francesco Di Raimondo, Sergio Siragusa

Erschienen in: Annals of Hematology | Ausgabe 10/2009

Einloggen, um Zugang zu erhalten

Abstract

The evidence that leukocytes may contribute to the pathogenesis of thrombosis in Chronic Myeloproliferative Neoplasms is increasing but not definitive. To further enforces whether an increased leukocyte count is associated with thrombosis and whether this effect can be modulated by cytoreductive therapy, we analyzed the clinical course of 187 patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) followed at two Italian Institutions over a period of 7 years. The association was measured at diagnosis or before thrombotic events: a multivariable analysis was carried out using data at baseline and time-dependent covariates. We found that white blood cells (WBC) count above 9.5 × 109/L at diagnosis (baseline analysis) was associated with thrombosis during the follow-up (Hazard Ratio [HR] of 1.8, p 0.03). At the time-dependent analysis, therapy with hydroxyurea (HU), lowering by 35% the baseline WBC level, reduced such strength of association giving a HR of 1.3 (p value non significant). We found a trend between WBC level and thrombosis in untreated low-risk patients (RR of 1.9, 95% CI 0.9 to 3.1); in high-risk patients treated with HU this correlation was clearly lost (RR 1.1, 95% CI 0.2 to 2.7). Finally, we could not identify the presence of JAK2 V617F as a risk factor for thrombosis. Properly designed prospective studies should corroborate such results.
Literatur
1.
Zurück zum Zitat Elliott MA, Tefferi A (2005) Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 128:275–90PubMedCrossRef Elliott MA, Tefferi A (2005) Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 128:275–90PubMedCrossRef
2.
Zurück zum Zitat Marchioli R, Finazzi G, Landolfi R et al (2005) Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 23:2224–32PubMedCrossRef Marchioli R, Finazzi G, Landolfi R et al (2005) Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 23:2224–32PubMedCrossRef
3.
Zurück zum Zitat Passamonti F, Rumi E, Pungolino E et al (2004) Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 117:755–61PubMedCrossRef Passamonti F, Rumi E, Pungolino E et al (2004) Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 117:755–61PubMedCrossRef
4.
Zurück zum Zitat Wolanskyj AP, Schwager SM, McClure RF et al (2006) Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc 81:159–66PubMedCrossRef Wolanskyj AP, Schwager SM, McClure RF et al (2006) Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc 81:159–66PubMedCrossRef
5.
Zurück zum Zitat Falanga A, Marchetti M, Barbui T et al (2005) Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: the role of neutrophils. Semin Hematol 42:239–247PubMedCrossRef Falanga A, Marchetti M, Barbui T et al (2005) Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: the role of neutrophils. Semin Hematol 42:239–247PubMedCrossRef
6.
Zurück zum Zitat Arellano-Rodrigo E, Alvarez-Larran A, Reverter JC et al (2006) Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica 91:169–175PubMed Arellano-Rodrigo E, Alvarez-Larran A, Reverter JC et al (2006) Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica 91:169–175PubMed
7.
Zurück zum Zitat Wolanskyj AP, Lasho TL, Schwager SM et al (2005) JAK2V617F mutation in essential thrombocythaemia: clinical implications and long-term prognostic relevance. Br J Haematol 131:208–213PubMedCrossRef Wolanskyj AP, Lasho TL, Schwager SM et al (2005) JAK2V617F mutation in essential thrombocythaemia: clinical implications and long-term prognostic relevance. Br J Haematol 131:208–213PubMedCrossRef
8.
Zurück zum Zitat Carobbio A, Finazzi G, Guerini V et al (2007) Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors and Jak2 mutation status. Blood 109:2310–3PubMedCrossRef Carobbio A, Finazzi G, Guerini V et al (2007) Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors and Jak2 mutation status. Blood 109:2310–3PubMedCrossRef
9.
Zurück zum Zitat Landolfi R, Di Gennaro L, Barbui T et al (2007) Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 109:2446–52PubMedCrossRef Landolfi R, Di Gennaro L, Barbui T et al (2007) Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 109:2446–52PubMedCrossRef
10.
Zurück zum Zitat Kundranda MN, Maiti B, Iqbal N et al (2008) The association of leukocytosis, thrombocytosis and JAK2V617F mutation with thrombotic events in myeloproliferative disorders (MPD’s). Blood 112:2803 (Abs)CrossRef Kundranda MN, Maiti B, Iqbal N et al (2008) The association of leukocytosis, thrombocytosis and JAK2V617F mutation with thrombotic events in myeloproliferative disorders (MPD’s). Blood 112:2803 (Abs)CrossRef
11.
Zurück zum Zitat Murphy S, Peterson P, Iland H et al (1997) Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival and leukemic transition by treatment. Semin Hematol 34:29–39PubMed Murphy S, Peterson P, Iland H et al (1997) Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival and leukemic transition by treatment. Semin Hematol 34:29–39PubMed
12.
Zurück zum Zitat Pearson TC, Messinezy M, Westwood N, et al. (2000). A polycythemia vera updated: diagnosis, pathobiology, and treatment. Hematology Am Soc Hematol Educ Program 51-68 Pearson TC, Messinezy M, Westwood N, et al. (2000). A polycythemia vera updated: diagnosis, pathobiology, and treatment. Hematology Am Soc Hematol Educ Program 51-68
13.
Zurück zum Zitat Barbui T, Finazzi G (2005) When and how to treat essential thrombocythemia. New Engl J Med 353:85–86PubMedCrossRef Barbui T, Finazzi G (2005) When and how to treat essential thrombocythemia. New Engl J Med 353:85–86PubMedCrossRef
14.
Zurück zum Zitat Baxter EJ, Scott LM, Campbell PJ et al (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054–1061PubMed Baxter EJ, Scott LM, Campbell PJ et al (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054–1061PubMed
15.
Zurück zum Zitat Gangat N, Strand J, Li CY et al (2007) Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. Br J Haematol 138(3):354–8PubMedCrossRef Gangat N, Strand J, Li CY et al (2007) Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. Br J Haematol 138(3):354–8PubMedCrossRef
16.
Zurück zum Zitat Campbell PJ, Scott LM, Buck G et al (2005) Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 366:1945–1953PubMedCrossRef Campbell PJ, Scott LM, Buck G et al (2005) Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 366:1945–1953PubMedCrossRef
17.
Zurück zum Zitat Cheung B, Radia D, Pantelidis P et al (2005) The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia. Br J Haematol 132:244–250CrossRef Cheung B, Radia D, Pantelidis P et al (2005) The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia. Br J Haematol 132:244–250CrossRef
18.
Zurück zum Zitat Antonioli E, Guglielmelli P, Pancrazzi A et al (2005) Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia 19:1847–1849PubMedCrossRef Antonioli E, Guglielmelli P, Pancrazzi A et al (2005) Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia 19:1847–1849PubMedCrossRef
19.
Zurück zum Zitat Dahabreh IJ, Zoi K, Giannouli S et al (2009) Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia. Leuk Res 33(1):67–73PubMedCrossRef Dahabreh IJ, Zoi K, Giannouli S et al (2009) Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia. Leuk Res 33(1):67–73PubMedCrossRef
20.
Zurück zum Zitat Ziakas PD (2008) Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain. Haematologica 93:1412–1414PubMedCrossRef Ziakas PD (2008) Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain. Haematologica 93:1412–1414PubMedCrossRef
21.
Zurück zum Zitat Carobbio A, Antonioli E, Guglielmelli P et al (2008) Leukocytosis and risk stratification assessment in essential thrombocythemia. J Clin Oncol 26(16):2732–6PubMedCrossRef Carobbio A, Antonioli E, Guglielmelli P et al (2008) Leukocytosis and risk stratification assessment in essential thrombocythemia. J Clin Oncol 26(16):2732–6PubMedCrossRef
22.
Zurück zum Zitat Gangat N, Wolanskyj A, Schwager S et al (2008) Leukocytosis at diagnosis and the risk of subsequent thrombosis in low-risk essential thrombocythemia and polycythemia vera. Blood 112:1751 (Abs) Gangat N, Wolanskyj A, Schwager S et al (2008) Leukocytosis at diagnosis and the risk of subsequent thrombosis in low-risk essential thrombocythemia and polycythemia vera. Blood 112:1751 (Abs)
Metadaten
Titel
Correlation between leukocytosis and thrombosis in Philadelphia-negative chronic myeloproliferative neoplasms
verfasst von
Domenica Caramazza
Clementina Caracciolo
Rita Barone
Alessandra Malato
Giorgia Saccullo
Valeria Cigna
Salvatore Berretta
Luciana Schinocca
Gerlando Quintini
Vincenzo Abbadessa
Francesco Di Raimondo
Sergio Siragusa
Publikationsdatum
01.10.2009
Verlag
Springer-Verlag
Erschienen in
Annals of Hematology / Ausgabe 10/2009
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-009-0706-x

Weitere Artikel der Ausgabe 10/2009

Annals of Hematology 10/2009 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.